Clinical trials: Mild Chronic Obstructive Pulmonary Disease
Chronic Obstructive Pulmonary Disease
SILO2 (Signal Intensity Lung washOut)
Chronic Obstructive Pulmonary Disease (COPD) is a leading and still increasing cause of disease and death worldwide, affecting those in both developed and developing countries.
- Trial name
- SILO2 (NCT02024737)
- Testing
- MRI lung imaging (not an intervention per se but the focus of the study)
- Where
- United Kingdom
- Volunteers
- 5 people
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
Chronic Hepatitis B
A Clinical Study Evaluating the Pharmacokinetic Characteristics and Safety of AHB-137 Injection in Participants With Mild to Moderate Liver Dysfunction and Those With Normal Liver Function.
A clinical study evaluating the pharmacokinetic characteristics and safety of AHB-137 injection in participants with mild to moderate liver dysfunction and those with normal liver function.
- Trial name
- NCT07600788
- Testing
- AHB-137 injection
- Where
- 5 sites in China
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Ausper Biopharma Co., Ltd.
Chronic Obstructive Pulmonary Disease
Clinical Study to Investigate the Pharmacokinetics, Safety and Tolerability Following Single Administration of CHF6001 in Subjects With Mild, Moderate and Severe Liver Impairment in Comparison With Matched Healthy Control Subjects
A clinical trial to investigate the pharmacokinetics, safety and tolerability of CHF6001 after single administrations in participants with mild, moderate and severe liver impairment with matched healthy adult volunteers
- Trial name
- NCT05373953
- Testing
- CHF6001
- Where
- Bulgaria
- Volunteers
- 44 people, healthy volunteers welcome
- Sponsor
- Chiesi Farmaceutici S.p.A.
Acute Exacerbation of Chronic Obstructive Pulmonary Disease
Effect of Compound Sodium Chlorate and Aminophylline Tablets on Chronic Obstructive Pulmonary Disease(COPD).
Acute exacerbation of chronic obstructive pulmonary disease (AECOPD) is an important event in the management of chronic obstructive pulmonary disease.
- Trial name
- NCT04101500
- Testing
- Compound Ipratropium Bromide Solution(C1) for Inhalation, Compound Sodium Chlolate and Aminophylline Tablets(C2)
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Asthma Control, Asthma
A Community-Based Swimming and Inspiratory Muscle Training Intervention to Promote Physical Activity and Asthma Control in Children With Mild Asthma
This randomized controlled trial investigated the effects of adding inspiratory muscle training (IMT) to a structured swimming program on pulmonary function, respiratory muscle strength, ventilatory capacity, perceived exertion…
- Conditions
- Asthma Control, Asthma, Asthma Chronic
- Trial name
- IMT-SWIM-ASTHM (NCT07394127)
- Testing
- Swimming Training Only (Control Group), Swimming + Inspiratory Muscle Training (Experimental Group)
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people
- Sponsor
- Gümüşhane Universıty
Chronic Obstructive Pulmonary Disease
Endotoxin and Inflammatory Markers in Healthy Non-Smokers and Current Smokers Including Patients With Chronic Obstructive Pulmonary Disease (COPD)
The primary aim of this study is to investigate the effects of inhaled lipopolysaccharide endotoxin (LPS) on bronchial and alveolar exhaled nitric oxide (NO) and NO metabolites and other inflammatory markers and mediators in…
- Trial name
- NCT00159289
- Testing
- Inhalation of LPS
- Where
- United Kingdom
- Volunteers
- healthy volunteers welcome
- Sponsor
- Imperial College London
Asthma (Part 1), COPD (Part 2)
Two-part Safety, Tolerability, Pharmacodynamic and -Kinetic Study of Inhaled AZD8871 in Asthmatic and COPD Subjects
This is a phase I, randomised, placebo-controlled 2-part study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of AZD8871 delivered by inhalation, in asthmatic and chronic obstructive pulmonary disease…
- Trial name
- NCT02573155
- Testing
- Dose 1, AZD8871 50 μg (Part 1), Dose 2, AZD8871 100 μg (Part 1), Dose 3, AZD8871 300 μg (Part 1)
- Where
- 2 sites in United Kingdom
- Volunteers
- 134 people
- Sponsor
- AstraZeneca